KK
ARQT icon

KLP Kapitalforvaltning’s Arcutis Biotherapeutics ARQT Stock Holding History

KLP Kapitalforvaltning’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$637K Hold
24,300
– – ﹤0.01% 1393
2026
Q1 		$573K Buy
24,300
+1,200
+5% +$30.6K ﹤0.01% 1366
2025
Q4 		$671K Buy
23,100
+1,300
+6% +$33.3K ﹤0.01% 1261
2025
Q3 		$411K Hold
21,800
– – ﹤0.01% 1491
2025
Q2 		$306K Buy
21,800
+3,300
+18% +$46.3K ﹤0.01% 1597
2025
Q1 		$289K Sell
18,500
-5,700
-24% -$80.3K ﹤0.01% 1579
2024
Q4 		$337K Buy
+24,200
New +$265K ﹤0.01% 1583

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KLP Kapitalforvaltning's ARQT Position: Q2 2026 in Review

KLP Kapitalforvaltning held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 24,300 shares worth $637K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

KLP Kapitalforvaltning first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $671K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • KLP Kapitalforvaltning held 24,300 shares of Arcutis Biotherapeutics worth $637K as of Q2 2026.
  • KLP Kapitalforvaltning left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1393 holding.
  • KLP Kapitalforvaltning first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • KLP Kapitalforvaltning's Arcutis Biotherapeutics position peaked at $671K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.